2020
Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesCarcinoma, HepatocellularFemaleHepatectomyHIV InfectionsHospitals, VeteransHumansImmunologic SurveillanceKaplan-Meier EstimateLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesConceptsBarcelona Clinic Liver Cancer stageHIV statusHepatocellular carcinomaUninfected patientsHIV infectionTumor characteristicsUninfected personsPathology reportsVeterans Aging Cohort StudyLiver tissue samplingCohort of HIVMultivariable Cox regressionAdvanced hepatic fibrosisAging Cohort StudyLiver Cancer stageRisk of deathBackground hepatic parenchymaCohort studyHazard ratioLymphovascular invasionBCLC stageImproved survivalCox regressionHistologic featuresHepatic fibrosis
2016
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miró JM, Sterne JAC, Collaboration F, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases 2016, 62: 1571-1577. PMID: 27025828, PMCID: PMC4885653, DOI: 10.1093/cid/ciw183.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnti-Retroviral AgentsCD4 Lymphocyte CountCohort StudiesFemaleHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedYoung AdultConceptsStart of ARTMortality rate ratiosCombination antiretroviral therapyAntiretroviral therapyMortality of patientsCD4 countMortality rateLow baseline CD4 countYears of ARTBaseline CD4 countHigher baseline CD4Collaborative Cohort StudyStart of treatmentNorth American cohortStrong inverse associationLong-term survivalShort-term survivalBaseline CD4CD4 groupCohort studyInverse associationPatientsAmerican cohortYears durationMortalityThe Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality. Journal Of General Internal Medicine 2016, 31: 492-501. PMID: 26847447, PMCID: PMC4835362, DOI: 10.1007/s11606-015-3571-4.Peer-Reviewed Original ResearchConceptsSubstance use disordersGuideline-concordant careCause mortalityOpioid therapyLong-term opioid therapyUntreated substance use disordersCurrent substance use disorderTerm opioid therapyTime-updated covariatesPrimary care visitsImportant clinical outcomesMulti-modal treatmentUrine drug testingUninfected patientsUntreated patientsCare visitsChronic painClinical outcomesCox regressionDecreased riskHigh comorbidityMortality burdenRehabilitative therapySUD treatmentHigh risk
2015
CD8+ T‐Cells Count in Acute Myocardial Infarction in HIV Disease in a Predominantly Male Cohort
Badejo OA, Chang CC, So-Armah KA, Tracy RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR, Kraemer K, Samet JH, Tindle HA, Goetz MB, Rodriguez-Barradas MC, Bedimo R, Gibert CL, Leaf DA, Kuller LH, Deeks SG, Justice AC, Freiberg MS. CD8+ T‐Cells Count in Acute Myocardial Infarction in HIV Disease in a Predominantly Male Cohort. BioMed Research International 2015, 2015: 246870. PMID: 25688354, PMCID: PMC4320893, DOI: 10.1155/2015/246870.Peer-Reviewed Original ResearchConceptsT-cell countsAcute myocardial infarctionVeterans Aging Cohort Study Virtual CohortCells/mm3AMI riskMyocardial infarctionT cellsUninfected peopleIncident acute myocardial infarctionEffect of CD8HIV viral loadCardiovascular disease riskHuman immunodeficiency virusT cell levelsBaseline CD8High CD8Low CD8Antiretroviral therapyCVD riskHIV diseaseViral loadImmunodeficiency virusCD8High riskCD4
2014
An Adapted Frailty-Related Phenotype and the VACS Index as Predictors of Hospitalization and Mortality in HIV-Infected and Uninfected Individuals
Akgün KM, Tate JP, Crothers K, Crystal S, Leaf DA, Womack J, Brown TT, Justice AC, Oursler KK. An Adapted Frailty-Related Phenotype and the VACS Index as Predictors of Hospitalization and Mortality in HIV-Infected and Uninfected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: 397-404. PMID: 25202921, PMCID: PMC4213242, DOI: 10.1097/qai.0000000000000341.Peer-Reviewed Original ResearchConceptsHIV-1 RNAUndetectable HIV-1 RNAVACS IndexUninfected individualsHazard ratioC-statisticFrailty-related phenotypePredictors of hospitalizationCohort Study participantsLow physical activityAdverse health outcomesPhysiologic reserveGeriatric syndromesFrailty stateRisk factorsHospitalizationPhysical activityMortality riskHIVHealth behaviorsHealth outcomesSurvival analysisSystem biomarkersStudy participantsMortality
2013
Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States
Collaboration T, del Amo J, Jarrin I, May M, Dabis F, Crane H, Podzamczer D, Sterling T, Abgrall S, Lampe F, Justice A, Castagna A, Boesecke C, Staehelin C, De Wolf F, Guest J, Mugavero M, Khaykin P, Samji H, Ingle S, Sterne J, Gill M. Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases 2013, 56: 1800-1809. PMID: 23457077, DOI: 10.1093/cid/cit111.Peer-Reviewed Original ResearchConceptsAdjusted mortality hazard ratioAntiretroviral therapyCause mortalityHazard ratioAIDS mortalityHuman immunodeficiency virus-positive subjectsLower mortalityNon-AIDS mortalityAfrican AmericansMortality hazard ratioVirus-positive subjectsAIDS mortality ratesCanadian First Nations peopleFirst Nations peopleCohort studyUS patientsCox regressionEuropean patientsHealthy migrantMortality ratePatientsHigh mortalityMortalityEthnicity/raceDeath ratePredictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 149-163. PMID: 23187941, PMCID: PMC3619393, DOI: 10.1097/qai.0b013e31827df36c.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAlanine TransaminaseAnti-Retroviral AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesCreatinineFemaleHemoglobinsHepatitis CHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralSex FactorsConceptsNet reclassification improvementVeterans Aging Cohort Study (VACS) IndexVeterans Affairs Healthcare SystemAntiretroviral therapyPatient subgroupsNorth American AIDS Cohort CollaborationHIV-1 RNA levelsStudy indicesObserved mortalityPrior ART exposureVACS Index scoreHIV-1 RNAImportant patient subgroupsRisk of mortalityHealthcare systemDiverse patient subgroupsCohort CollaborationHIV biomarkersVACS IndexHIV infectionOrgan injuryParametric survival modelsART exposureReclassification improvementC-statistic
2010
Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value?
Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value? Value In Health 2010, 13: 535-542. PMID: 20345544, PMCID: PMC3032536, DOI: 10.1111/j.1524-4733.2010.00714.x.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionNonadherent patientsAdherence interventionsRelative riskRisk factorsAntiretroviral therapy adherence interventionsEffect sizeNonadherence risk factorsBehavioral risk factorsHIV careAntiretroviral adherencePatientsNonadherenceSocietal perspectiveIncremental costIntervention costsSmall effect sizesLife expectancyInterventionRisk reductionPlausible effect sizes
2009
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDS
2008
Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study
Rodriguez-Barradas MC, Goulet J, Brown S, Goetz MB, Rimland D, Simberkoff MS, Crothers K, Justice AC. Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study. Clinical Infectious Diseases 2008, 46: 1093-1100. PMID: 18444830, PMCID: PMC3115628, DOI: 10.1086/529201.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccineVeterans Aging CohortPPV vaccinationIncidence of pneumoniaAging CohortCox proportional hazards regression methodsLow CD4 cell countsProportional hazards regression methodsCD4 cell countHIV infection statusRisk of pneumoniaLower hemoglobin levelsBenefits of vaccinationHuman immunodeficiency virusOngoing prospective studyElectronic medical recordsPneumococcal vaccinationPneumonia eventsUnvaccinated patientsCurrent smokingPneumococcal diseasePolysaccharide vaccineVaccination statusHIV infectionRetrospective review